Rituximab’s Efficacy in Patients With Hypersensitivity Reactions
نویسندگان
چکیده
Background: The B-cell antigen CD20 is expressed on normal B-cells and almost all lymphomas. This non-modulating agent provides an excellent target for antibody-directed therapeutic regimens. IDECC2B8 (rituximab) a monoclonal antibody (mAb) directed against the B-cell-specific CD20. mediates complement antibody-dependent cell-mediated cytotoxicity. As its usage has surged, there have been growing concerns about rituximab-related infusion reactions. Approximately 1/4th of patients receiving first administration show reactions, most time they are re-challenged safely. Since recent studies reported presence serum anti-rituximab antibodies in who develop hypersensitivity we evaluating pharmacodynamic response rituximab with it.
منابع مشابه
Hypersensitivity reactions
Hypersensitivity refers to undesirable (damaging, discomfort producing and sometimes fatal) reactions produced by the normal immune system. Hypersensitivity reactions require a pre-sensitized (immune) state of the host. Hypersensitivity reactions can be divided into four types: type I, type II, type III and type IV, based on the mechanisms involved and time taken for the reaction. Frequently, a...
متن کاملMetal Hypersensitivity in Orthodontic Patients
Orthodontic treatment of individuals with metal hypersensitivity is a matter of concern for the orthodontist. Orthodontic appliances contain metals like Nickel, Cobalt and Chromium etc. Metals may cause allergic reactions and are known as allergens. Reaction to these metals is due to biodegradation of metals in the oral cavity. This may lead to the formation of corrosion products and their expo...
متن کاملHypersensitivity reactions associated with fidaxomicin use.
We report hypersensitivity reactions associated with fidaxomicin, an antibacterial drug approved for the treatment of Clostridium difficile-associated diarrhea. These reactions are viewed as significant because of severity and unexpected because fidaxomicin is minimally absorbed. The fidaxomicin labeling was revised to include information about the possibility of hypersensitivity reactions.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of pharmaceutics & pharmacology
سال: 2023
ISSN: ['2327-204X']
DOI: https://doi.org/10.13188/2327-204x.1000034